GLEN ALLEN, Virginia, October 18, 2011 /PRNewswire/ --
Rock Creek Pharmaceuticals, a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), has announced the expansion of international shipping destinations for purchases of its dietary supplement, Anatabloc™. As the company indicated in an August 30 release that announced the product launch, Anatabloc™ contains the dietary ingredient anatabine citrate. Anatabine is an alkaloid that is found in a variety of plants in the Solinacea family, including the tobacco plant, as well as in eggplant, green peppers and green tomatoes. Anatabine citrate, combined with Vitamins A and D3, is believed to assist the body in maintaining anti-inflammatory support. Excess inflammation is linked with a variety of auto-immune conditions that includes thyroid dysfunction, arthritis and Alzheimer's disease.
Rock Creek launched capacity for shipments to Canada, the United Kingdom, Australia and New Zealand, as well as 13 countries located in Europe, the Middle East and Asia, in late September. Effective today Anatabloc can be shipped to an additional 29 countries: Portugal, Monaco, Iceland, Hungary, Bulgaria, Poland, Austria, Finland, Norway, Sweden, Denmark, Brazil, Peru, Uruguay, Aruba, Bermuda, Barbados, Antigua, Cayman Islands, British Virgin Islands, Turks and Caicos, Bahamas, St. Lucia, St. Kitts and Nevis, San Marino, New Caledonia and Mexico.
Consumers interested in purchasing the product will be able to either choose a "drop-down menu" on the product website (http://www.anatabloc.com) that contains a list of all countries to which shipping is available, or to call the customer service center at 1-800-778-2031. The company plans to continue exploring options for shipping to additional countries around the world, based on consumer demand for Anatabloc™. As new countries are added, they will be included in the shipping menu on the product website.
The company also announced that it is hosting the first of a series of Anatabloc conferences for physicians this evening in Richmond, Virginia. Presentations on research using anatabine will be made by Michael Mullan, M.D. PhD, Director of the Roskamp Institute; Paul Ladenson, MD, Director of Endocrinology & Metabolism at the Johns Hopkins School of Medicine; and Patrizio Caturegli, MD, MPH, Associate Professor of Pathology and Endocrinology at the John Hopkins School of Medicine. Rock Creek intends to host two additional conferences for physicians and allied health care professionals in the Midwest and on the West Coast later this month. Physicians and other licensed providers interested in viewing the presentations can contact firstname.lastname@example.org for access.
Certain statements in this press release other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "continues," "likely," "may," "opportunity," "potential," "projects," "will," "expects," "plans," "intends" and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties, factors and contingencies include, without limitation, the challenges inherent in new product development initiatives through Star Tobacco and Rock Creek, the uncertainties inherent in the progress of scientific research, our ability to raise additional capital in the future that is necessary to maintain our business, potential disputes concerning our intellectual property, risks associated with litigation regarding such intellectual property, uncertainties associated with the development, testing and regulatory approvals of our low-TSNA tobacco, related tobacco products and pharmaceutical and nutraceutical products , market acceptance of our new smokeless tobacco products and nutraceutical and pharmaceutical products, competition from companies with greater resources than us, our dependence on key employees and on our prior strategic relationships with Brown & Williamson Tobacco Corporation in light of its combination with R.J. Reynolds Tobacco Company, Inc.
Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that the expectations will be attained or that any deviation will not be material. See additional discussion under "Risk Factors" in the Company's Annual Report on Form 10-K as filed with the SEC on March 16, 2011, and other factors detailed from time to time in the Company's other filings with the SEC, available at http://www.sec.gov. All information in this release is current as of this date, and the Company undertakes no obligation to update or advise upon any such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
About Star Scientific
Star Scientific is a technology-oriented company with a mission to reduce the harm associated with tobacco at every level. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins, principally through the utilization of the innovative StarCured® tobacco curing technology. Its subsidiary, Rock Creek Pharmaceuticals, Inc., is involved in the development of nutraceuticals as well as products to address neurological and mood disorders. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, D.C. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.
See Star's website at: http://www.starscientific.com
Sara Troy Machir
Vice President, Communications & Investor Relations
SOURCE Star Scientific